DanielDanick @DanielDanick: "🔔🔔 $LLY launches new..."

Spain

🔔🔔 $LLY (Eli Lilly & Co) launches new weight loss drug at lower price point 🔔🔔 Pharmaceutical company $LLY Lilly began offering initial doses of its low-cost weight loss drug, Zepbound, in single-dose vials, a move the company says will significantly increase the drug's availability. Its popularity has resulted in shortages in the United States, leading some people to turn to versions of the drug prepared at compounding pharmacies. According to Patrik Jonsson, president of Cardiometabolic Health and Lilly USA, the introduction of the new vials will not only allow them to meet high demand, but will also expand access for patients seeking a safe and effective treatment option. The new vials will be available exclusively to self-pay individuals through LillyDirect, a company platform that facilitates telemedicine services and prescription management for patients. The price for a four-week supply of 2.5-milligram vials is $399, while the same amount in 5-mg vials is $529. These prices are less than half the list value of other GLP-1 obesity drugs, according to $LLY Lilly. 🏆We continue to hold $LLY Lilly in our PORTFOLIO with a weight of 6.5%. 🏆 We believe that it has great growth potential and, even though it has already generated 51% of profitability so far this year, we believe that its maximum potential is yet to come. 👍💪Follow me for new PORTFOLIO updates and relevant market information $LLY $NOVO-B.CO (Novo Nordisk B A/S) $NVO (Novo-Nordisk A/S SPONS ADR) $NVDA (NVIDIA Corporation) $GOLD